We're developing innovative treatments for Alzheimer's disease.
R&D
Screening Platform
Excavation of new drug candidate based on screening platform
Misfolded Protein
Disaggregators and clearance enhancers will help eliminate the toxic amyloid-β and Tau
Accumulation of neurotoxic proteins, amyloid-β and tau, is a unique event of Alzheimer's disease.
We have faith that reversing and/or eliminating this abnormality is the key approach to end the fatal neurodegeneration.
We have faith that reversing and/or eliminating this abnormality is the key approach to end the fatal neurodegeneration.
Glia
Controlling the immune system in the brain will have the potential to treat Alzheimer's disease
Our first-in-class drug candidates rescue abnormal glia, impaired by amyloid-β and tau, in Alzheimer’s brain to its normal state.